Clinical Trials Logo

Clinical Trial Summary

Mountain sport activities as for example hiking or skiing may involve the risk of adverse health events especially in older people not accustomed to the specific mountain sport at altitude or people with pre-existing health issues. Increased activation of the sympathetic nervous system and abrupt changes in heart rate and blood pressure are thought to trigger these adverse effects. Preventive measures include regular physical activity (i.e. training) and adequate medical treatment. Hypoxia pre-adaptation (e.g., pre-adapt one night at moderate altitude) and pre-conditioning (e.g., intermittent hypoxia (IH) training), which was shown to lead to some favorable sympathetic nervous system, ventilatory and metabolic adaptations and additionally exerts anti-inflammatory action, could be hypothesized of being a further preventive measure. The aim of this research project is to investigate whether intermittent hypoxia pre-conditioning or sleeping one night at altitude (i.e., current recommendation before practicing mountain leisure sports in the elderly) is able to increase oxygen saturation during passive hypoxia exposure and during simulated hiking and skiing at altitude. Additionally, it is aimed to investigate whether such procedure reduces the physiological responses (i.e., heart rate, its variability and blood pressure (including baroreflex sensitivity) responses as well as metabolic, ventilatory, inflammatory and redox responses) during these activities.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04725539
Study type Interventional
Source Institute of Mountain Emergency Medicine
Contact Hannes Gatterer, PhD
Phone +39 0471 055 578
Email hannes.gatterer@eurac.edu
Status Recruiting
Phase N/A
Start date January 1, 2022
Completion date December 31, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT05292079 - CAPTURER PMCF Study ( rEPIC04D )
Recruiting NCT05292118 - Navitian PMCF Study ( rEPIC04C )
Recruiting NCT05292014 - ANGIOLITE PMCF Study ( rEPIC04F )
Recruiting NCT05292092 - Essential Pro PMCF Study ( rEPIC04E )
Completed NCT05292105 - NC Xperience PMCF Study( rEPIC04B)
Completed NCT01435031 - EXPERT CTO: Evaluation of the XIENCE PRIME™ LL and XIENCE Nano™ Everolimus Eluting Coronary Stent Coronary Stents, Performance, and Technique in Chronic Total Occlusions N/A
Terminated NCT01443754 - Hybrid Revascularisation by Combined Coronary Artery Bypass Graft (CABG) and PCI in Multivessel Coronary Disease N/A
Completed NCT00783302 - Study in Subjects Suspected of Having CAD Undergoing VISIPAQUE-enhanced CCTA as Part of Their Routine Medical Care N/A
Completed NCT00543400 - Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE) Phase 2
Completed NCT05516784 - Impact of CYP2C19 Genotype-guided Clopidogrel and Ticagrelor Treatment on Platelet Function Test and Metabolomics Profile Phase 4
Completed NCT02873052 - MyoVista Measurements in Patients With Atherosclerosis and CAD
Terminated NCT02984891 - Optical Coherence Tomography (OCT) Intravascular Ultrasound (IVUS) Dual Imaging
Completed NCT05292144 - Xperience Pro PMCF Study
Completed NCT02554292 - Post Market Surveillance of SeQuent Please Neo With Scoring Balloon
Active, not recruiting NCT06052319 - A Study to Assess the Engagement and Usefulness of Care4Today Digital Platform for Disease Management in Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD) Population
Completed NCT00265525 - Evaluation of a Web-based Intervention to Promote Physical Activity in Patients With Heart Disease. Phase 3
Completed NCT03570697 - Imaging of Coronary Plaques in Participants Treated With Evolocumab Phase 3
Terminated NCT05508893 - Screening for Coronary Artery Disease USing Primary Evaluation With Coronary CTA in Aviation Medicine (SUSPECT) N/A
Completed NCT02341664 - Patient and Provider Assessment of Lipid Management Registry
Completed NCT02098772 - Phase III Study Comparing Two Methods of Cardioplegia in Aortic Valve Surgery Custodiol-N Versus Custodiol Phase 3